Gene Therapies Are Expected To Start Being Used In Common Diseases Such As Cancer And Heart Disease.

Gene Therapies In 2029 - Could They Be Used For Cancer And Heart Disease?

Gene therapy promises a revolution in inherited diseases through one-time treatments that correct missing or faulty genes. In 2025, the FDA approved Waskyra (etuvetidigene autotemcel) for Wiskott-Aldrich syndrome and gene therapies for severe leukocyte adhesion deficiency. These approvals represent concrete examples demonstrating that gene therapy is becoming a reality in rare diseases. But can this success extend to more common illnesses like cancer and heart disease by 2029?

Is There An Anticipated Increase In Gene Therapy Approvals?

A significant increase in the number of gene therapy approvals, along with expansion into new indications, is expected by 2029. The current outlook predicts that this success will initially spread to more rare diseases, followed by more common inherited conditions such as hemophilia and sickle cell anemia. However, expanding into complex illnesses like cancer and heart disease is viewed as a much longer-term and uncertain goal. Therefore, the projected 50% probability for 2029 reflects an optimistic but cautious approach.

What Barriers Stand In The Way Of Gene Therapy In Cancer And Heart Disease?

High costs, vector safety, and production capacity remain key barriers. Because cancer and heart disease are not caused by a single gene mutation, targeting them with gene therapy is considerably more complex. Furthermore, there’s currently insufficient long-term efficacy and safety data for these diseases. Therefore, claims of “curing all diseases” in the distant future should be approached with caution.

What Are Realistic Expectations For 2029?

By 2029, gene therapy is likely to receive further approvals for conditions such as hemophilia, beta-thalassemia, and certain types of leukemia. For heart disease and solid tumors, clinical trials are expected to continue progressing, but widespread approval may not occur until the late 2030s. The FDA’s 2025 approval of Waskyra demonstrated an acceleration in rare diseases, but more research and infrastructure investment are needed for a transition to common illnesses.

Frequently Asked Questions

When Will Gene Therapy Become Standard Treatment For Cancer?

Currently, gene-based approaches such as CAR-T cell therapies are being used in leukemia and lymphoma. However, becoming a standard treatment for solid tumors (lung, breast, etc.) may not occur until the late 2030s. In 2029, expansion is expected primarily in blood cancers.

Will The Cost Of Gene Therapies Decrease By 2029?

As production capacity increases and new vector technologies develop, costs are expected to decrease somewhat. However, one-time treatments will likely remain in the hundreds of thousands of dollars range. Payment models and government support will play a critical role at this point.

Can Gene Therapy Prevent Heart Attacks?

Heart disease arises from the complex interplay of genetic and environmental factors. Currently, gene therapy can target single-gene-caused heart risks such as familial hypercholesterolemia. To prevent widespread heart attacks, ongoing research using gene editing (CRISPR) to permanently lower cholesterol levels is underway, but the probability of clinical use in 2029 is low.